Aprepitant versus Olanzapine in Patients of Breast Cancer on Adriamycin and Cyclophosphamide Regimen - Role in Effectiveness of Prevention of Nausea and Vomiting.

Acta Med Litu · 2025 · PMC12239174 · PMID 40641531

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

13.5% for Aprepitant), indicates a potential trend favouring Olanzapine, although the results did not reach statistical significance levels.

also in 111,027 other papers

showed a trendno p-value reported

It also showed a trend towards superior efficacy in delayed nausea, though statistical significance was not reached.

also in 53,322 other papers

a positive trendno p-value reported

Similar results of a positive trend for Olanzapine were also reported in other studies [ 17 ].

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.